Arthneeti
IC

Innova Captab Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Innova Captab Q2 Results 2026: PAT ₹42 Cr, Revenue ₹496 Cr

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹496Cr
Net profit
₹42Cr
Margin
14.1%

Innova Captab Ltd Q2 FY27 key numbers

Revenue
CDMO Services & Products revenue for Q2 FY27 was ₹345.2 crore, up 30% YoY.

As stated in Innova Captab Ltd's Q2 FY27 investor presentation · published 13 Nov 2026. Reported figures, not investment advice.

Based on Innova Captab Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,172
Market cap₹6.7K Cr
P/E43.5

The short version

Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11). EBITDA for Q2 FY27: ₹72.4 crore, up 29.2% YoY from ₹56.1 crore in Q2 FY26.

From Innova Captab Ltd's Q2 FY27 earnings-call transcript · updated 13 Nov 2026.

How did Innova Captab's revenue grow in the September 2026 quarter?

  • Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11).
  • CDMO Services & Products revenue for Q2 FY27 was ₹345.2 crore, up 30% YoY (Page 11).
  • Branded Generics revenue for Q2 FY27 was ₹151.1 crore, reflecting a 32% YoY growth (Page 11).
  • Total Income (including other income) for Q2 FY27 was ₹498.8 crore, up 29.7% YoY (Page 13).

2 more points from Innova Captab Ltd's call on revenue

Create a free account to keep reading this call

What happened to Innova Captab's margins in Q2 FY27?

EBITDA for Q2 FY27: ₹72.4 crore, up 29.2% YoY from ₹56.1 crore in Q2 FY26

Locked: what Innova Captab Ltd said on margins

Also locked on this page: fundraising, order book

Free account, 30 seconds. No card needed.

What capex is Innova Captab planning?

  • Jammu Plant:
  • Total capital investment: ₹480+ crore
  • Commercialized in January 2025
  • Currently ramping up with multiple client audits completed
  • Expected GST-linked incentives of 300% of investment for 10 years
  • 6% p.a. capital interest subvention on loan against eligible capex
  • Capacity utilization expected to reach optimum in 5-6 years
  • Baddi Plant (established 2006):
  • Nearing optimal utilization with strong demand
  • Dehradun & Taloja Plants:
  • Expansion ongoing, part of capacity growth plan
  • Capacity Utilization Targets:
  • FY26 un-utilized capacity ranges between 5%-60% across plants
  • Ramp-up expected over 2-6 years to optimum utilization
  • Strategic Expansion:
  • Acquisition of Sharon Bio Medicine Ltd in 2023

2 more points from Innova Captab Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1Ind-Swift Laboratories
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Innova Captab raising money or cutting debt?

Borrowings (financial liabilities) have changed over the years:

Locked: what Innova Captab Ltd said on fundraising

Also locked on this page: margins, order book

Free account, 30 seconds. No card needed.

How big is Innova Captab's order book?

See what Innova Captab Ltd said on order book & pipeline — free account, 30 seconds.

Innova Captab Ltd — Quarterly revenue & net profit

Revenue Net profit
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27

Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.

Innova Captab Ltd Q2 FY27 results — key figures

Innova Captab Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue496
Operating profit (EBITDA)70
Operating margin14.1%
Profit before tax56
Net profit (PAT)42
EPS (₹)7.41

Source: Innova Captab Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹471 Cr, net profit ₹44 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Continue your research

What Innova Captab's management said in earlier quarters

Earlier calls (6)

Others in Pharmaceuticals & Biotechnology this season

  • Viyash Scientific (Q2 FY27)

    Q2 FY27 revenue from operations: ₹9,879 million, up 16.2% YoY (Page 8) . Key investor presentation takeaways from Viyash Scientific Ltd's Q2 FY27 investor prese

  • Natco Pharma (Q2 FY27)

    EBITDA for Q2 FY27: INR 3,100 Mn, down from INR 6,792 Mn in Q2 FY26 (54.4% decline) . Key investor presentation takeaways from Natco Pharma Ltd's Q2 FY27 invest

  • Vineet Laborator (Q2 FY27)

    Year-on-year change: Decrease of approximately INR 323.65 lakh or about 18.58% decline . Key results statement takeaways from Vineet Laboratories Ltd's Q2 FY27

  • Balaxi Pharma (Q2 FY27)

    34.1% increase (from Rs. Key results statement takeaways from Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Innova Captab Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Innova Captab Ltd Q2 FY27 results?

Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11). EBITDA for Q2 FY27: ₹72.4 crore, up 29.2% YoY from ₹56.1 crore in Q2 FY26.

What is Innova Captab Ltd share price analysis?

Innova Captab Ltd currently shows a neutral. The stock trades at a P/E of 43.5 with a market cap of ₹6,695 Cr. Investors should review the full earnings analysis for detailed insights.

Is Innova Captab Ltd planning capital expenditure?

Jammu Plant:.

Keep Innova Captab Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.